Biomoda, Inc. Retains MicroCap Management, LLC as its Lead Corporate Communications and Broker Relations Firm.
John Cousins, President of Biomoda announced, "MicroCap has the tools andconnections to spread the word to the wider investment community about Biomodaand its potential." Alan Siegel, Managing Director of MicroCap Management, LLCstated: "We are thrilled to have Biomoda on board, and we're extremelyenthusiastic about the future of this program."
MicroCap Management, LLC, headquartered in Orlando, Florida, is aCorporate Communications and Broker Relations firm that utilizesbusiness-to-business marketing strategies and extensive relationships withmajor investment web portals to promote growth for publicly traded companies.Its Managing Directors possess 30+ years experience in marketing andadvertising for OTC and Fortune 500 companies, and its highly trained BrokerRelations staff has established relationships with broker/dealers nationwide,thereby providing maximum worldwide exposure to broker/dealers,investment bankers, wholesale and retail traders, as well as hedge fundmanagers and the global investment community.
MicroCap Management has its hands on the pulse of Wall Street, generatingexposure and driving liquidity through its free Lead Generator Program andBroker Relations Campaigns; thereby creating a niche that traditional IR andPR firms haven't tapped.
MicroCap Management's core philosophy is to allow its corporate clients tofocus on core business while managing its corporate communications and brokerrelations, and in doing so has frequently taken micro cap companies that wereonce acorns to a market penetration level of mature oak trees. As a sidebenefit, these strategies often assist in building the consumer markets aswell, which in turn can contribute to increased shareholder equity.
Additionally, MicroCap Management's programs help companies meetpre-requisite criteria to qualify for listing on premier exchanges such asNASDAQ, AMEX and NYSE.
Biomoda's patented technology, a non-invasive cytology based assay, isdesigned for cancer screening of large populations at a reasonable cost.Current diagnostic methods for lung cancer, including CT scans and X-rays,often detect the disease only at more advanced stages and are relativelyexpensive.
SOURCE Biomoda, Inc.
You May Also Like